- Part 7: For the preceding part double click ID:nRSH4027Rf
Biologics Price Competition and Innovation Act within the ACA, which
contains general directives for biosimilar applications. The FDA issued
final guidance in April 2015 on implementing an abbreviated biosimilar
approval pathway. In March 2015, the FDA approved the first biosimilar
product submitted under the abbreviated biosimilar pathway. However,
significant questions remain, including standards for designation of
interchangeability and data collection requirements to support
extrapolation of indications. In addition, due to the recent submissions
and approvals of abbreviated biosimilar applications, a number of legal
challenges construing the requirements of the abbreviated biosimilar
pathway are under review. For example, in July 2015, the US Court of
Appeals for the Federal Circuit held that biosimilar applicants were not
- More to follow, for following part double click ID:nRSH4027Rh